Skip to content

Exploring the use of network pharmacology methods based on the theory of "wet stasis and volt heat" to investigate the effect of "TongFengHeJi" on improving endothelial function by reshaping the vascular microenvironment

Exploring the use of network pharmacology methods based on the theory of "wet stasis and volt heat" to investigate the effect of "TongFengHeJi" on improving endothelial function by reshaping the vascular microenvironment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000898
Enrollment
Unknown
Registered
2025-05-07
Start date
2024-01-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GOUT

Interventions

Acute phase A group :add TongFengHeJi
Acute phase B group :not add TongFengHeJi
Control group:No intervention
Relief period:No intervention

Sponsors

Jiangsu Integrated Traditional Chinese and Western Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age between 18 and 75 years old (including boundary values) gender not limited; (2) Patients in the acute and remission phases meet the diagnostic criteria for gouty arthritis; (3) Voluntarily participate in the experiment and sign the informed consent form; (4) The control group of healthy individuals had normal blood uric acid levels.

Exclusion criteria

Exclusion criteria: (1) Allergic constitution such as any known research drug (2) Combined with potentially life threatening diseases such as serious cardiovascular diseases brain diseases liver diseases kidney diseases hematological diseases lung diseases or diseases that can directly affect survival such as cancer or AIDS; (3) Merge patients with severe liver and kidney dysfunction (4) Patients with peptic ulcers accompanied by bleeding or perforation; (5) Patients with infectious diseases including tuberculosis hepatitis B etc; (6) Has participated in other ongoing clinical researchers; (7) Those who have planned to have children within 6 months or are pregnant or breastfeeding; (8) Individuals with mental illness and lack of autonomous behavioral ability; (9) Individuals with a history of drug or alcohol abuse; (10) Has the potential to reduce the likelihood of enrollment and other easily lost to follow-up situations; (11) Patients in the remission period have not used uric acid lowering drugs or have been steadily using related drugs for more than 2 weeks.

Design outcomes

Primary

MeasureTime frame
HIF-1a;ESR;ICAM-1;VEGF;Urine PH;ET-1;IL-2\IL-4\IL-6\IL-10\TNF-a\IFN-?;carbon dioxide combining power;Plasma lactate;CRP;NO;

Secondary

MeasureTime frame
the frequency of using Etoricoxib;echocardiography;EPO;Time for improvement of joint pain;uric acid change value;Carotid artery endothelial thickness;

Countries

China

Contacts

Public ContactYang Yaxu

Jiangsu Integrated Traditional Chinese and Western Medicine Hospital

463697018@qq.com18936881199

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026